Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death

Cancer Cell

Volumn 12, Issue 1, 2007, Pages 66-80

  Ricci, M Stacey ^a,b   Kim, Seok Hyun ^a,b   Ogi, Kazuhiro ^a,b   Plastaras, John P ^a,b   Ling, Jianhua ^d   Wang, Wenge ^a,b   Jin, Zhaoyu ^a,b   Liu, Yingqiu Y ^a,b   Dicker, David T ^a,b   Chiao, Paul J ^d   Flaherty, Keith T ^a   Smith, Charles D ^c   El Deiry, Wafik S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CELLCYCLE

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN MCL 1; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CANCER; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SENSITIZATION; SIGNAL TRANSDUCTION;

EID: 34347246278     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.05.006     Document Type: Article

References (54)

1. Askew D., Ashmum R., Simmons B., and Cleveland J.L. Constitutive c-myc expression in an IL-3 dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6 (1991) 1915-1922
2. Burns T.F., and El-Deiry W.S. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276 (2001) 37879-37886
3. Clohessy J.G., Zhuang J., de Boer J., Gil-Gomez G., and Brady H.J. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J. Biol. Chem. 281 (2006) 5750-5759
4. Cowling V., and Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ. 9 (2002) 1046-1056
5. Creagh E.M., Murphy B.M., Duriez P.J., Duckett C.S., and Martin S.J. Smac/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins. J. Biol. Chem. 279 (2004) 26906-26914
6. Cuconati A., Mukherjee C., Perez D., and White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 17 (2003) 2922-2932
7. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., and Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69 (1992) 119-128
8. Gregory M.A., Qi Y., and Hann S.R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 278 (2003) 51606-51612
9. Harper N., Farrow S.N., Kaptein A., Cohen G.M., and MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. J. Biol. Chem. 276 (2001) 34743-34752
10. Hu W.H., Johnson H., and Shu H.B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. 274 (1999) 30603-30610
11. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
12. Ito C.Y., Kazantsev A.G., and Baldwin Jr. A.S. Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res. 22 (1994) 3787-3792
13. Jin Z., and El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol. Ther. 4 (2005) 139-163
14. Juin P., Hueber A.O., Littlewood T., and Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 13 (1999) 1367-1381
15. Juin P., Hunt A., Littlewood T., Griffiths B., Swigart L.B., Korsmeyer S., and Evan G. c-Myc functionally cooperates with Bax to induce apoptosis. Mol. Cell. Biol. 22 (2002) 6158-6169
16. Keller U., Nilsson J.A., Maclean K.H., Old J.B., and Cleveland J.L. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene 24 (2005) 6231-6240
17. Kelley S.K., and Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4 (2004) 333-339
18. Kim S.H., Kim K., Kwagh J.G., Dicker D.T., Herlyn M., Rustgi A.K., Chen Y., and El-Deiry W.S. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J. Biol. Chem. 279 (2004) 40044-40052
19. Klefstrom J., Arighi E., Littlewood T., Jaattela M., Saksela E., Evan G.I., and Alitalo K. Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. EMBO J. 16 (1997) 7382-7392
20. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., Fong S., Schwall R., Sinicropi D., and Ashkenazi A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8 (2002) 274-281
21. Maurer U., Charvet C., Wagman A.S., Dejardin E., and Green D.R. Glycogen Synthase Kinase-3 Regulates Mitochondrial Outer Membrane Permeabilization and Apoptosis by Destabilization of MCL-1. Mol. Cell 21 (2006) 749-760
22. Mitchell K.O., Ricci M.S., Miyashita T., Dicker D.T., Jin Z., Reed J.C., and El-Deiry W.S. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res. 60 (2000) 6318-6325
23. Morel J., Audo R., Hahne M., and Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 280 (2005) 15709-15718
24. Moshynska O., Sankaran K., Pahwa P., and Saxena A. Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J. Natl. Cancer Inst. 96 (2004) 673-682
25. Nishihara H., Hwang M., Kizaka-Kondoh S., Eckmann L., and Insel P.A. Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J. Biol. Chem. 279 (2004) 26176-26183
26. O'Connor L., Strasser A., O'Reilly L.A., Hausmann G., Adams J.M., Cory S., and Huang D.C. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17 (1998) 384-395
27. Ozoren N., and El-Deiry W.S. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4 (2002) 551-557
28. Rahmani M., Maynard Davis E., Bauer C., Dent P., and Grant S. Apoptopsis induced by the kinase inhibitor Bay 43-9006 in human leukemia cells involves downregulation of MCL-1 through inhibition of translation. J. Biol. Chem. 280 (2005) 35217-35227
29. Ravi R., and Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res. 62 (2002) 1583-1587
30. Reed J.C., Doctor K.S., and Godzik A. The domains of apoptosis: a genomics perspective. Sci. STKE 2004 (2004) re9
31. Ricci M.S., Jin Z., Dews M., Yu D., Thomas-Tikhonenko A., Dicker D.T., and El-Deiry W.S. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell. Biol. 24 (2004) 8541-8555
32. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16 (1997) 6914-6925
33. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., and Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17 (1998) 1675-1687
34. Scorrano L., Ashiya M., Buttle K., Weiler S., Oakes S.A., Mannella C.A., and Korsmeyer S.J. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev. Cell 2 (2002) 55-67
35. Shiozaki E.N., Chai J., Rigotti D.J., Riedl S.J., Li P., Srinivasula S.M., Alnemri E.S., Fairman R., and Shi Y. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11 (2003) 519-527
36. Shu H.B., Halpin D.R., and Goeddel D.V. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 6 (1997) 751-763
37. Sitcheran R., Gupta P., Fisher P.B., and Baldwin A.S. Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J. 24 (2005) 510-520
38. Soucie E.L., Annis M.G., Sedivy J., Filmus J., Leber B., Andrews D.W., and Penn L.Z. Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol. Cell. Biol. 21 (2001) 4725-4736
39. Tanaka H., Matsumura I., Ezoe S., Satoh Y., Sakamaki T., Albanese C., Machii T., Pestell R.G., and Kanakura Y. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell 9 (2002) 1017-1029
40. Tran S.E., Holmstrom T.H., Ahonen M., Kahari V.M., and Eriksson J.E. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276 (2001) 16484-16490
41. Ueda Y., Hirai S., Osada S., Suzuki A., Mizuno K., and Ohno S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem. 271 (1996) 23512-23519
42. Viatour P., Merville M.P., Bours V., and Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 30 (2005) 43-52
43. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., and Baldwin Jr. A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
44. Wang J.M., Chao J.R., Chen W., Kuo M.L., Yen J.J., and Yang-Yen H.F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol. 19 (1999) 6195-6206
45. Wang W., and El-Deiry W.S. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol. Ther. 2 (2003) 196-202
46. Wang Y., Engels I.H., Knee D.A., Nasoff M., Deveraux Q.L., and Quon K.C. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5 (2004) 501-512
47. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., and Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
48. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
49. Yang Q.H., Church-Hajduk R., Ren J., Newton M.L., and Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev. 17 (2003) 1487-1496
50. Yang Q.H., and Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J. Biol. Chem. 279 (2004) 16963-16970
51. You Z., Madrid L.V., Saims D., Sedivy J., and Wang C.Y. c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor kappa B transactivation. J. Biol. Chem. 277 (2002) 36671-36677
52. Yu C., Bruzek L.M., Meng X.W., Gores G.J., Carter C.A., Kaufmann S.H., and Adjei A.A. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24 (2005) 6861-6869
53. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
54. Zhang X.D., Borrow J.M., Zhang X.Y., Nguyen T., and Hersey P. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22 (2003) 2869-2881